Severe congenital neutropenia

Neutrophils are an important defense against bacteria and fungi. In severe congenital neutropenia, their production or survival is impaired, often causing serious infections from early life.

This is a group of disorders, not a single gene diagnosis. It is distinct from neutropenia caused by medicines, immune disease or other acquired causes. Cyclic neutropenia has a different pattern, even though variants in the same gene can sometimes cause either condition.

ELANE is a common genetic cause, but several other genes are involved. Some forms mainly affect neutrophils; others can also affect development, metabolism or other organs.

Inheritance may be dominant, recessive or X-linked depending on the gene, and a variant can arise for the first time in a child. Genetic assessment helps explain family risks and may influence monitoring and treatment.

Possible problems include mouth ulcers, gum disease, skin infections, abscesses and pneumonia. A low neutrophil count can also allow infection to become serious quickly, so families need a clear plan for fever or other concerning symptoms.

Some forms carry increased risks of myelodysplastic neoplasms or acute myeloid leukemia. That risk is not a prediction of an individual outcome. Blood and marrow monitoring look for changes that may alter care.

Granulocyte colony-stimulating factor, or G-CSF, encourages neutrophil production. It is commonly given by injection, with dose and schedule tailored to blood counts, infections and side effects. Antibiotics and dental care remain important.

Many people obtain useful infection control with G-CSF. A poor response, substantial treatment requirements or continuing serious infections can prompt transplant assessment. Myelodysplastic or leukemic changes are also important indications.

Allogeneic transplantation can replace the abnormal blood-forming system. Its timing reflects the genetic disorder, marrow findings, infection history, age, organ health and donor options. There is no single rule that all people respond to G-CSF or that transplant is needed only after leukemia develops.

Ongoing care may include injections, blood tests, dental visits and periodic marrow examinations. These demands can affect school, work and travel, even when treatment is controlling infections.

Before transplantation, the team discusses conditioning, fertility effects, graft failure, graft-versus-host disease and infection risk. Any features of the genetic condition outside the blood system may need continued care afterward.

A suitable unrelated donor can provide an established transplant route when a matched relative is unavailable. Relatives are assessed for the familial genetic condition as well as their HLA match.

The need for a donor is determined by the individual disease course. Successful growth-factor treatment and careful surveillance remain important options, and neither diagnosis nor a single low count establishes that a registry search is necessary.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?